Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01767454
Title Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Ipilimumab + Trametinib

Dabrafenib + Ipilimumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site Los Angeles California 90025 United States Details
GSK Investigational Site San Francisco California 94115 United States Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site Saint Louis Missouri 63110 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Nashville Tennessee 37232 United States Details
GSK Investigational Site Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field